Malignant pleural mesothelioma: An update on biomarkers and treatment

Chest

Volumn 136, Issue 3, 2009, Pages 888-896

  Ray, Mandira ^a   Kindler, Hedy Lee ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CRS 207; CYANOCOBALAMIN; DOXORUBICIN; EDATREXATE; EPIRUBICIN; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; IMMUNOTOXIN SS1P; METHOTREXATE; MITOMYCIN; MONOCLONAL ANTIBODY MORAB 009; NAVELBINE; OXALIPLATIN; PEMETREXED; RALTITREXED; SUNITINIB; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; VINBLASTINE; VORINOSTAT;

ADD ON THERAPY; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; GENETIC PREDISPOSITION; HEMATOLOGIC DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG RESECTION; MAINTENANCE THERAPY; MINER; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OCCUPATIONAL EXPOSURE; OCCUPATIONAL TOXICOLOGY; PAIN; PLEURA MESOTHELIOMA; PLEURECTOMY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION INJURY; RADIATION PNEUMONIA; REVIEW; SIMIAN VIRUS 40; THORACOSCOPY; THORAX RADIOGRAPHY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

EID: 70049098328     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-2665     Document Type: Article

References (75)

1. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17:260-271
2. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004; 159:107-112
3. Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92:587-593
4. Joshi TK, Gupta RK. Asbestos in developing countries: magnitude of risk and its practical implications. Int J Occup Med Environ Health 2004; 17:179-185 (Pubitemid 38480469)
5. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007; 25:1489-1497 (Pubitemid 46759253)
6. Roushdy-Hammady I, Siegel J, Emri S, et al. Geneticsusceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001; 357:444-445 (Pubitemid 32156148)
7. Cristaudo A, Foddis R, Vivaldi A, et al. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res 2005; 65:3049-3052 (Pubitemid 40524583)
8. Manfredi JJ, Dong J, Liu WJ, et al. Evidence against a role for SV40 in human mesothelioma. Cancer Res 2005; 65:2602-2609 (Pubitemid 40490058)
9. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients: part 1. Diagnosis. Cancer 1993; 72:389-393 (Pubitemid 23193443)
10. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005; 129: 1407-1414
11. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996; 14:1-12 (Pubitemid 26079510)
12. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113:723-731
13. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16:145-152 (Pubitemid 28041592)
14. Fennell DA, Parmar A, Shamash J, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma, based on 3 consecutive phase II trials. J Clin Oncol 2005; 23:184-189 (Pubitemid 41702637)
15. Scherpereel A, Lee YCG. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007; 13:339-343
16. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-1616
17. Pass HI, Wall A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 1:265-272 (Pubitemid 350265805)
18. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 17:5076-5081 (Pubitemid 47502073)
19. Grigoriu BD, Chahine B, Vachani A, et al. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 2009; 179:950-954
20. Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006; 12:4225-4231
21. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353:1564-1573 (Pubitemid 41434635)
22. Park E-K, Thomas PS, Johnson AR, et al. Osteopontin levels in a asbestos-exposed population. Clin Cancer Res 2009; 15:1362-1366
23. Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothlelioma. J Thorac Oncol 2008; 3:851-857
24. Beyer HL, Geschwindt RD, Glover CL, et al. Mesomark: a potential test for malignant pleural mesothelioma. Clin Chem 2007; 53:666-672 (Pubitemid 46580236)
25. Park E-K, Sandrini A, Yates DH, et al. Soluble mesothelinrelated protein in an asbestos-exposed population: the Dust Diseases Board Cohort study. Am J Respir Crit Care Med 2008; 178:832-837
26. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008; 135:620-626
27. Treasure T, Tan C, Lang-Lazdunski L, et al. The MARS trial: mesothelioma and radical surgery. Interact Cardiovasc Thorac Surg 2006; 5:58-59 (Pubitemid 43200170)
28. Davies HE, Musk AW, Lee YC. Prophyllactic radiotherapy for pleural puncture sites: the controversy continues. Curr Opin Pulm Med 2008; 14:326-330
29. Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005; 63:1045-1052 (Pubitemid 41505282)
30. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 122:788-795 (Pubitemid 33590380)
31. Rice DC, Smythe WR, Liao Z, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2007; 2:350-357 (Pubitemid 47381562)
32. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy inmalignant pleural mesothelioma. Ann Oncol 2007; 7:1196-1202 (Pubitemid 47244366)
33. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27:3007-3013
34. Kindler HL. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 2008; 9:171-179
35. Lerner HJ, Schoenfeld DA, Martin A, et al. Malignant mesothelioma: the Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983; 52:1981-1985
36. Krug LM. An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am 2005; 19:1117-1136
37. Berghmans T, Lafitte JJ, Paesmans M, et al. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer 2005; 50:75-82 (Pubitemid 41297472)
38. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002; 38:111-121 (Pubitemid 35157753)
39. Solheim OP, Saeter G, Finnanger AM, et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: a phase II study. Br J Cancer 1992; 65:956-960
40. Kindler HL, Belani CP, Herndon JE, et al. Edatrexate (10-ethyl-deaza- aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma: sequential phase II trials by the Cancer and Leukemia Group B. Cancer 1999; 86:1985-1991
41. Wang Y, Zhao R, Chattopadhyay S, et al. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed. Cancer Res 2002; 62:6434-6437 (Pubitemid 35364101)
42. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21:1556-1561
43. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-2644 (Pubitemid 46606305)
44. Chattopadhyay S, Tamari R, Min SH, et al. Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 2007; 12:808-815 (Pubitemid 47328224)
45. Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007; 12:20-37 (Pubitemid 46143500)
46. Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24:1443-1448 (Pubitemid 46622011)
47. Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19:370-373 (Pubitemid 351201722)
48. Ceresoli GL, Castagneto B, Zucali PA, et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 2008; 99:51-56 (Pubitemid 351920240)
49. O'Brien ME, Watkins D, Ryan C, et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006; 17:270-275
50. van den Bogaert DP, Pouw EM, van Wijhe G, et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2006; 1:25-30 (Pubitemid 47164017)
51. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or with out raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23:6881-6889 (Pubitemid 46260274)
52. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17:25-30 (Pubitemid 29022374)
53. Lee CW, Murray N, Anderson H, et al. Outcomes with a platinum plus gemcitabine or pemetrexed as first-line systemic therapy for malignant pleural mesothelioma in British Columbia: a review of province-wide practice [abstract]. J Thorac Oncol 2007; 2:S606
54. Kalmadi SR, Rankin C, Kraut MJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008; 60:259-263 (Pubitemid 351609140)
55. Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003; 97:2791-2797 (Pubitemid 36605147)
56. Schutte W, Blankenburg T, Lauerwald K, et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 2003; 4:294-297 (Pubitemid 36546414)
57. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18:3912-3917
58. Sorensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008; 99:44-50 (Pubitemid 351920221)
59. Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2008; 63:94-97
60. Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371:1685-1694 (Pubitemid 351671885)
61. Cortese JF, Gowda AL, Wali A, et al. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 2006; 118:521-522 (Pubitemid 41779097)
62. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007; 25: 2406-2413 (Pubitemid 46999211)
63. Govindan R, Kratzke RA, Herndon JE 2nd, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005; 11:2300-2304
64. Dowell J, Kindler HL. Anti-angiogenic therapies for mesothelioma. Hematol Oncol Clin North Am 2005; 19:1137-1146
65. Bertino P, Piccardi F, Porta C, et al. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 2008; 14: 541-548 (Pubitemid 351226124)
66. Janne PA, Wang XF, Krug LM, et al. Sorafenib in malignant mesothelioma (MM): a phase II trial of the Cancer and Leukemia Group B (CALGB 30307) [abstract]. J Clin Oncol 2007; 25:7707
67. Baas P, Boogerd W, Dalesio O, et al. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005; 48:291-296 (Pubitemid 40501820)
68. Nowak AK, Millward MJ, Francis R, et al. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma [abstract]. J Clin Oncol 2008; 26:8063
69. Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma [abstract]. J Clin Oncol 2007; 25:7526
70. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberolylanilide hyroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923-3931 (Pubitemid 46218695)
71. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44:46-53
72. Hassan R, Broaddus VC, Wilson S, et al. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 2007; 13:7166-7171 (Pubitemid 350276903)
73. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007; 13:5144-5149 (Pubitemid 47502082)
74. Armstrong DK, Laheru D, Ma WW, et al. A phase 1 study of MORAb-009, a monoclonal antibody against mesothelin in pancreatic cancer, mesothelioma and ovarian adenocarcinoma [abstract]. J Clin Oncol 2007; 25:14041
75. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15:257-260 (Pubitemid 38262625)